Is Daiichi Sankyo Company, Limited (DSNKY) a Buy, Sell, or Hold?
OTC : DSNKY
Daiichi Sankyo Company, Limited — News
$17.06 USD
-$0.46 (-2.63%)
- Volume
- 37.33K
- Average Volume
- 325.47K
- Market Capitalization
- $31.04B
- P/E Ratio
- 19.62
- Dividend Yield
- 2.83%
- Price Target
- Year High
- $27.50
- Year Low
- $14.98
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.49
- Current Ratio
- $2.42
| Source | Headline |
|---|---|
|
Daiichi Sankyo (OTCMKTS:DSNKY) & Shuttle Pharmaceuticals (NASDAQ:SHPH) Head to Head Contrast
Shuttle Pharmaceuticals (NASDAQ: SHPH - Get Free Report) and Daiichi Sankyo (OTCMKTS:DSNKY - Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, analyst recommendations, dividends, earnings and institutional ownership. Insider and Institutional Ownership 4.6% of Shuttle Pharmaceuticals defenseworld.net - 2026-07-22 01:15:09 |
|
Daiichi Sankyo: Not Exciting Enough For This Market, Apparently
Daiichi Sankyo maintains strong growth prospects, driven by its expanding antibody-drug conjugate (ADC) pipeline and disciplined oncology development. Trastuzumab deruxtecan remains a key growth driver, with ongoing label expansions and pivotal trial readouts expected in 2H 2026 for first-line lung cancer. Datopotamab deruxtecan and raludotatug deruxtecan have secured new approvals and promising data, broadening the company's oncology franchise beyond HER2. seekingalpha.com - 2026-07-01 12:02:17 |
|
Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca's (LSE/STO/NYSE: AZN) Datroway® (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sank. businesswire.com - 2026-05-22 09:30:00 |
|
Daiichi Sankyo Company, Limited (DSNKY) Q4 2026 Earnings Call Transcript
Daiichi Sankyo Company, Limited (DSNKY) Q4 2026 Earnings Call Transcript seekingalpha.com - 2026-05-11 16:20:44 |
|
Daiichi Sankyo Unveils New Five-Year Business Plan Focused on Oncology Leadership and Innovation
TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) today revealed its next Five-Year Business Plan (FY2026 - FY2030) that outlines how the company plans to deliver more than 2.3 trillion yen in oncology revenue by 2030 and be a global top five oncology company by 2035 as part of its larger 2035 Vision to be recognized as a “trusted healthcare innovator transforming the lives of people through science and technology.” The new Five-Year Business Plan reinforces the enduring purpose of Daiichi San. businesswire.com - 2026-05-11 02:30:00 |
|
Waiv Enters Collaboration with Daiichi Sankyo to Deliver AI-Derived Biomarkers for ADC Program
PARIS--(BUSINESS WIRE)--Waiv, formerly Owkin Dx, a Paris-based company catalyzing AI precision testing, today announced it has entered a collaboration with Daiichi Sankyo (TSE: 4568) to lead digital pathology biomarker discovery for an antibody-drug conjugate (ADC) program. With deep expertise across diverse pathology and multimodal data, and a global data network spanning academic institutions, hospitals, and laboratories, Waiv has a proven track record delivering AI-powered biomarker solution. businesswire.com - 2026-05-06 08:00:00 |
